Progression-free survival as endpoint in metastatic RCC? (Q34656803)

3 August 2017

title

Progression-free survival as endpoint in metastatic RCC? (English)

1 reference

3 August 2017

Jennifer J Knox

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

22 July 2008

1 reference

3 August 2017

1 reference

3 August 2017

volume

372

1 reference

3 August 2017

issue

9637

1 reference

3 August 2017

page(s)

427-429

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961040-5

7 January 2021

10.1016/S0140-6736(08)61040-5

Identifiers

DOI

1 reference

3 August 2017

1 reference